Data gathered: May 30
Alternative Data for Larimar Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 14 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,117 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 70 | Sign up | Sign up | Sign up |
About Larimar Therapeutics
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
| Price | $2.18 |
| Target Price | Sign up |
| Volume | 252,840 |
| Market Cap | $127M |
| Year Range | $1.71 - $9.29 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside PotentialMay 21 - Yahoo Entertainment |
 |
14,078 Shares in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Acquired by Graham Capital Management L.P.May 20 - ETF Daily News |
|
Balyasny Asset Management L.P. Makes New $308,000 Investment in Larimar Therapeutics, Inc. (NASDAQ:LRMR)May 18 - ETF Daily News |
|
Voya Investment Management LLC Decreases Stock Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR)May 16 - ETF Daily News |
|
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $19.63 Consensus Price Target from AnalystsMay 14 - ETF Daily News |
|
Algert Global LLC Buys Shares of 12,190 Larimar Therapeutics, Inc. (NASDAQ:LRMR)May 14 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -29M | -31M | -0.460 |
| Q4 '24 | 240,000 | 0 | 240,000 | -29M | -31M | -0.450 |
| Q3 '24 | 0 | 74,000 | -74,000 | -15M | -18M | -0.240 |
| Q2 '24 | 0 | 87,000 | -87,000 | -22M | -25M | -0.340 |
| Q1 '24 | 0 | 80,000 | -80,000 | -15M | -17M | -0.270 |
Insider Transactions View All
| Hamilton Thomas Edward filed to buy 564,798 shares at $8.7. May 31 '24 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) filed to buy 4,207,982 shares at $8.7. February 16 '24 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) filed to buy 6,151,406 shares at $8.7. February 16 '24 |
| THOMAS FRANK E filed to buy 2,000 shares at $11. February 15 '24 |
| Shankar Gopi filed to buy 5,000 shares at $3.7. December 8 '23 |
Similar companies
Read more about Larimar Therapeutics (LRMR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Larimar Therapeutics?
The Market Cap of Larimar Therapeutics is $127M.
What is the current stock price of Larimar Therapeutics?
Currently, the price of one share of Larimar Therapeutics stock is $2.18.
How can I analyze the LRMR stock price chart for investment decisions?
The LRMR stock price chart above provides a comprehensive visual representation of Larimar Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Larimar Therapeutics shares. Our platform offers an up-to-date LRMR stock price chart, along with technical data analysis and alternative data insights.
Does LRMR offer dividends to its shareholders?
As of our latest update, Larimar Therapeutics (LRMR) does not offer dividends to its shareholders. Investors interested in Larimar Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Larimar Therapeutics?
Some of the similar stocks of Larimar Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.